An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 274-277

  Secchiero, Paola ^a   Corallini, Federica ^a   Beltrami, Antonio Paolo ^b   Ceconi, Claudio ^c   Bonasia, Vincenzo ^b   Di Chiara, Antonio ^b   Ferrari, Roberto ^c   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Acute myocardial infarction; Heart failure; OPG; TRAIL

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE HEART INFARCTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; MALE; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77952427166     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.11.005     Document Type: Article

References (15)

1. Zauli G., Secchiero P. The role of the TRAIL/TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cyt Growth Fact Rev 2006, 17:245-257.
2. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
3. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
4. Secchiero P., Corallini F., Pandolfi A., et al. An increased osteoprotegerin (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006, 169:2236-2244.
5. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
6. Shargorodsky M., Boaz M., Luckish A., et al. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009, 204:608-611.
7. Schoppet M., Sattler A.M., Schaefer J.R., Hofbauer L.C. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006, 184:446-447.
8. Niessner A., Hohensinner P.J., Rychli K., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009, 30:789-796.
9. Satoh D., Inami N., Shimazu T., et al. Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J Thromb Thrombolysis 2009, (June). [Epub ahead of print].
10. Zauli G., Pandolfi A., Gonelli A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003, 92:732-740.
11. Secchiero P., Corallini F., di Iasio M.G., Gonelli A., Barbarotto E., Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005, 105:3413-3419.
12. Secchiero P., Candido R., Corallini F., et al. Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 2006, 114:1522-1530.
13. Guidelines for the diagnosis of heart failure: the Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J 1995, 16:741-751.
14. Bennett B.J., Scatena M., Kirk E.A., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006, 26:2117-2124.
15. Ovchinnikova O., Gylfe A., Bailey L., et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2009, 29:1478-1480.